Magle Chemoswed Holding AB (52X) Stock Price & Analysis
52X Stock Chart & Stats
- Day’s Range
- EUR 0.01 - EUR 0.02
- 52-Week Range
- EUR 0.01 - EUR 1.91
- Previous Close
- EUR 0.01
- Volume
- N/A
- Average Volume (3M)
- 9
- Market Cap
- EUR 3.59M
- Enterprise Value
- EUR 363.38M
- Total Cash (Recent Filing)
- EUR 2.08M
- Total Debt (Recent Filing)
- EUR 343.99M
- Price to Earnings (P/E)
- ―
- Beta
- 0.46
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Positive TTM revenue growth indicates that customer demand for the company’s development and manufacturing services is still expanding despite current losses. Sustained top-line growth can support operating leverage and provide a broader revenue base from which profitability may recover.
Gross Margin
A gross margin of approximately 54% shows that the company retains meaningful value after direct production and service costs. This provides an underlying economic base for recovery if operating expenses become better aligned with revenue and customer project activity remains healthy.
CDMO And Life Science Positioning
Magle’s combination of pharmaceutical development, analytical work, API activity, and finished-dose manufacturing gives it several ways to serve regulated customers. This breadth can support durable relevance across customer programs while its own drug and medical technology projects add strategic optionality.
Bears Say
Severe Profitability Deterioration
The sharp move into a deeply negative net margin shows that current operating costs are overwhelming gross profit, even with revenue growth and a still-solid gross margin. Unless profitability improves, continued losses could restrict investment capacity and weaken the company’s ability to scale sustainably.
Negative Cash Generation
Operating and free cash flow near negative 110m indicate substantial ongoing cash burn rather than internally funded expansion. Persistent cash outflows can reduce financial flexibility, increase reliance on external funding, and make it harder to absorb execution challenges while investing in customer and proprietary projects.
Higher Leverage And Lower Equity Cushion
Debt now exceeds equity on a TTM basis, while the shrinking equity base reduces the balance-sheet cushion available to absorb further losses. Higher leverage can constrain capital allocation and increase financial risk if negative earnings and cash flow persist over the coming quarters.
Magle Chemoswed Holding AB News
52X FAQ
What was Magle Chemoswed Holding AB’s price range in the past 12 months?
What is Magle Chemoswed Holding AB’s market cap?
When is Magle Chemoswed Holding AB’s upcoming earnings report date?
How were Magle Chemoswed Holding AB’s earnings last quarter?
Is Magle Chemoswed Holding AB overvalued?
Does Magle Chemoswed Holding AB pay dividends?
What is Magle Chemoswed Holding AB’s EPS estimate?
How many shares outstanding does Magle Chemoswed Holding AB have?
What happened to Magle Chemoswed Holding AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Magle Chemoswed Holding AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Magle Chemoswed Holding AB
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process development and production of Active Pharmaceutical Ingredients (APIs), as well as the innovation and manufacturing of advanced wound care and diagnostic products, primarily leveraging its proprietary degradable starch microsphere technology. Its API portfolio features Warfarin sodium, used as an anticoagulant; Melperone hydrochloride, an antipsychotic agent; Isradipine, a calcium channel blocker for hypertension; Amantadine sulfate, for central nervous system disorders; and Benserazide hydrochloride, utilized with L-Dopa in Parkinson's disease treatment. Furthermore, Magle Chemoswed offers a range of medical devices for advanced wound care, surgical diagnostics, and drug delivery. These include EmboCept S, a microsphere-based device for vascular occlusion in liver and lung tumors; SmartGel, an innovative non-allergenic hydrogel derived from their microsphere platform; SmartPAN, a diagnostic tool for detecting pancreatic fluid leakage during surgical procedures; and EmboCept M, designed for managing benign prostatic hyperplasia. The company provides contract services to the pharmaceutical and medical device industries. Founded in 1944, Magle Chemoswed Holding AB (publ) operates as a subsidiary of Magle AB.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Aaron Wong
- Employees
- 150
- Website
- maglegroup.com
- Address
- Agneslundsvägen 27, Malmö, SN, 212 15, SE
Magle Chemoswed Holding AB (52X) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 2 | 11 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 4 | 0 | 8 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| SE:BINVBioInvent International AB | ||
| SE:NEEMS.BScandinavian ChemoTech AB Class B | ||
| SE:ELICElicera Therapeutics AB | ||
| SE:SPAGOSpago Nanomedical AB | ||
| SE:CANTACantargia AB |







